Research ExplorerPublicationsComparative diagnostic performance of ¹⁸F-FDG PET/CT versus ...

Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation

Standard

Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. / Derlin, Thorsten; Peldschus, Kersten; Münster, Silvia; Bannas, Peter; Herrmann, Jochen; Stübig, Thomas; Habermann, Christian R; Adam, Gerhard; Kröger, Nicolaus-Martin; Weber, Christoph.

In: EUR RADIOL, Vol. 23, No. 2, 01.02.2013, p. 570-8.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Derlin, T, Peldschus, K, Münster, S, Bannas, P, Herrmann, J, Stübig, T, Habermann, CR, Adam, G, Kröger, N-M & Weber, C 2013, 'Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation', EUR RADIOL, vol. 23, no. 2, pp. 570-8. https://doi.org/10.1007/s00330-012-2600-5

APA

Derlin, T., Peldschus, K., Münster, S., Bannas, P., Herrmann, J., Stübig, T., Habermann, C. R., Adam, G., Kröger, N-M., & Weber, C. (2013). Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. EUR RADIOL, 23(2), 570-8. https://doi.org/10.1007/s00330-012-2600-5

Vancouver

Derlin T, Peldschus K, Münster S, Bannas P, Herrmann J, Stübig T et al. Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. EUR RADIOL. 2013 Feb 1;23(2):570-8. https://doi.org/10.1007/s00330-012-2600-5

Bibtex

@article{c5e7e2833cbf47f990dfed1c52fb8106,
title = "Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation",
abstract = "OBJECTIVES: To compare the diagnostic performance of whole-body magnetic resonance imaging (WBMRI) versus (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) for determination of remission status in patients with multiple myeloma (MM) after stem cell transplantation (SCT).METHODS: Thirty-one patients were examined by both WBMRI and PET/CT after SCT. Imaging results and clinical remission status as determined by the clinical gold standard (Uniform Response Criteria) were compared.RESULTS: One hundred four lesions were detected in 21 patients. PET/CT had a sensitivity of 50.0 %, a specificity of 85.7 %, a positive predictive value of 62.5 %, a negative predictive value of 78.3 %, and an overall accuracy of 74.2 % for determination of remission status. MRI had a sensitivity of 80.0 %, a specificity of 38.1 %, a positive predictive value of 38.1 %, a negative predictive value of 80 %, and an overall accuracy of 51.6 %. Concordant results were observed in only 12 (11.5 %) of the 104 lesions.CONCLUSIONS: In the post-treatment setting, both FDG PET/CT and WBMRI provide information about the extent of disease, allowing for a more comprehensive evaluation of persisting or recurrent myeloma. MRI may often be false positive because of persistent non-viable lesions. Therefore, PET/CT might be more suitable than MRI for determination of remission status.",
keywords = "Adult, Aged, Cohort Studies, Confidence Intervals, Disease-Free Survival, Female, Fluorodeoxyglucose F18, Follow-Up Studies, Graft Survival, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Multimodal Imaging, Multiple Myeloma, Neoplasm Staging, Positron-Emission Tomography, Postoperative Care, Predictive Value of Tests, Stem Cell Transplantation, Survival Analysis, Time Factors, Tomography, X-Ray Computed, Treatment Outcome",
author = "Thorsten Derlin and Kersten Peldschus and Silvia M{\"u}nster and Peter Bannas and Jochen Herrmann and Thomas St{\"u}big and Habermann, {Christian R} and Gerhard Adam and Nicolaus-Martin Kr{\"o}ger and Christoph Weber",
year = "2013",
month = feb,
day = "1",
doi = "10.1007/s00330-012-2600-5",
language = "English",
volume = "23",
pages = "570--8",
journal = "EUR RADIOL",
issn = "0938-7994",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation

AU - Derlin, Thorsten

AU - Peldschus, Kersten

AU - Münster, Silvia

AU - Bannas, Peter

AU - Herrmann, Jochen

AU - Stübig, Thomas

AU - Habermann, Christian R

AU - Adam, Gerhard

AU - Kröger, Nicolaus-Martin

AU - Weber, Christoph

PY - 2013/2/1

Y1 - 2013/2/1

N2 - OBJECTIVES: To compare the diagnostic performance of whole-body magnetic resonance imaging (WBMRI) versus (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) for determination of remission status in patients with multiple myeloma (MM) after stem cell transplantation (SCT).METHODS: Thirty-one patients were examined by both WBMRI and PET/CT after SCT. Imaging results and clinical remission status as determined by the clinical gold standard (Uniform Response Criteria) were compared.RESULTS: One hundred four lesions were detected in 21 patients. PET/CT had a sensitivity of 50.0 %, a specificity of 85.7 %, a positive predictive value of 62.5 %, a negative predictive value of 78.3 %, and an overall accuracy of 74.2 % for determination of remission status. MRI had a sensitivity of 80.0 %, a specificity of 38.1 %, a positive predictive value of 38.1 %, a negative predictive value of 80 %, and an overall accuracy of 51.6 %. Concordant results were observed in only 12 (11.5 %) of the 104 lesions.CONCLUSIONS: In the post-treatment setting, both FDG PET/CT and WBMRI provide information about the extent of disease, allowing for a more comprehensive evaluation of persisting or recurrent myeloma. MRI may often be false positive because of persistent non-viable lesions. Therefore, PET/CT might be more suitable than MRI for determination of remission status.

AB - OBJECTIVES: To compare the diagnostic performance of whole-body magnetic resonance imaging (WBMRI) versus (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) for determination of remission status in patients with multiple myeloma (MM) after stem cell transplantation (SCT).METHODS: Thirty-one patients were examined by both WBMRI and PET/CT after SCT. Imaging results and clinical remission status as determined by the clinical gold standard (Uniform Response Criteria) were compared.RESULTS: One hundred four lesions were detected in 21 patients. PET/CT had a sensitivity of 50.0 %, a specificity of 85.7 %, a positive predictive value of 62.5 %, a negative predictive value of 78.3 %, and an overall accuracy of 74.2 % for determination of remission status. MRI had a sensitivity of 80.0 %, a specificity of 38.1 %, a positive predictive value of 38.1 %, a negative predictive value of 80 %, and an overall accuracy of 51.6 %. Concordant results were observed in only 12 (11.5 %) of the 104 lesions.CONCLUSIONS: In the post-treatment setting, both FDG PET/CT and WBMRI provide information about the extent of disease, allowing for a more comprehensive evaluation of persisting or recurrent myeloma. MRI may often be false positive because of persistent non-viable lesions. Therefore, PET/CT might be more suitable than MRI for determination of remission status.

KW - Adult

KW - Aged

KW - Cohort Studies

KW - Confidence Intervals

KW - Disease-Free Survival

KW - Female

KW - Fluorodeoxyglucose F18

KW - Follow-Up Studies

KW - Graft Survival

KW - Humans

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Multimodal Imaging

KW - Multiple Myeloma

KW - Neoplasm Staging

KW - Positron-Emission Tomography

KW - Postoperative Care

KW - Predictive Value of Tests

KW - Stem Cell Transplantation

KW - Survival Analysis

KW - Time Factors

KW - Tomography, X-Ray Computed

KW - Treatment Outcome

U2 - 10.1007/s00330-012-2600-5

DO - 10.1007/s00330-012-2600-5

M3 - SCORING: Journal article

C2 - 22843058

VL - 23

SP - 570

EP - 578

JO - EUR RADIOL

JF - EUR RADIOL

SN - 0938-7994

IS - 2

ER -